Skip to Main Content

Paper Details

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B.
JCO Precis Oncol
11
2022
Afatinib, Cancer, ErbB family tyrosine kinase, HER2, Human, Human Epidermal Growth Factor Receptor 2, Patients, Tumors, acneiform rash, adenocarcinoma of extra-mammary Paget disease of skin, advanced cancers, afatinib, anemia, anorexia, breast cancer, breast ductal carcinoma, dehydration, diarrhea, estrogen, estrogen receptor, fatigue, human, human epidermal growth factor receptor 2, lobular carcinoma, mucositis, nausea, patient, patients, single-nucleotide variants, tumor, tyrosine, vomiting
Author NameAffiliation
Philippe L BedardPrincess Margaret Cancer Centre
Eddy S YangUniversity of Alabama-Birmingham
Eddy S YangUniversity of Alabama-Birmingham
  • 1 - 3

Datasets

Release 1.2